Research programme: vitiligo therapy - SWITCH Biotech
Alternative Names: SWT 05.100; SWT 05.102; SWT 05.103; SWT 05100; SWT 05102; SWT 05103; Vitiligo therapies research programme - SWITCH BiotechLatest Information Update: 02 Jun 2005
Price :
$50 *
At a glance
- Originator SWITCH Biotech (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vitiligo
Most Recent Events
- 01 Mar 2005 Discontinued - Preclinical for Vitiligo in Germany (unspecified route)
- 01 Mar 2005 SWITCH Biotech has closed down
- 30 Mar 2004 SWITCH Biotech AG and Spirig Pharma AG have entered into an agreement to co-develop SWT 05.100 for vitiligo